15485-80-0

Basic information

• Product Name: 4H-1-BENZOPYRAN-4-ONE
• Synonyms: 7-Hydroxy-4’-nitroisoflavone
• CAS NO: 15485-80-0
• Molecular Formula: C₁₅H₉NO₅
• Molecular Weight: 283.24
• Mol File: 15485-80-0.mol
• Article Data: 12

Chemical Properties

• Melting Point: 290-292℃
• Boiling Point: 530.788 °C at 760 mmHg
• Flash Point: 274.811 °C
• Appearance: Pale yellow/Powder
• Density: 1.494 g/cm³
• Vapor Pressure: 6.98E-12mmHg at 25°C
• Refractive Index: 1.692
• Storage Temp.: 2-8°C
• PKA: 6.68±0.20(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 4H-1-BENZOPYRAN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-1-BENZOPYRAN-4-ONE(15485-80-0)
• EPA Substance Registry System: 4H-1-BENZOPYRAN-4-ONE(15485-80-0)

Safety Data

• Hazardous Substances Data: 15485-80-0(Hazardous Substances Data)

Usage

Uses

7-Hydroxy-4'-nitroisoflavone is used in the synthesis of iso flavones, Synthesis of daidzin, soflavone amide derivatives.

InChI:InChI=1/C15H9NO5/c17-11-5-6-12-14(7-11)21-8-13(15(12)18)9-1-3-10(4-2-9)16(19)20/h1-8,17H

Upstream product

• 104-03-0 4-nitrobenzeneacetic acid 
• 15485-63-9 1-(2,4-dihydroxyphenyl)-2-(4-nitrophenyl)ethanone 
• 124-63-0 methanesulfonyl chloride 
• 68-12-2 N,N-dimethyl-formamide 
• 108-46-3 recorcinol 
• 15485-74-2 7-hydroxy-3-(4-nitro-phenyl)-4-oxo-4H-chromene-2-carboxylic acid ethyl ester 
• 555-21-5 4-Nitrophenylacetonitrile 
• 137522-88-4 7-Formyloxy-3-(4-nitrophenyl)-4H-1-benzopyran-4-one 
• 122-51-0 orthoformic acid triethyl ester 
• 137522-86-2 7-hydroxy-3-(4-nitro-phenyl)-4-oxo-4H-chromene-2-carboxylic acid 

Downstream Products

• 1426687-83-3 3-(4-nitrophenyl)-4-oxo-4H-chromen-7-yl trifluoromethanesulfonate 
• 1426687-87-7 3-(4-(methylsulfonamido)phenyl)-4-oxo-4H-chromen-7-yl trifluoromethanesulfonate 
• 1426687-85-5 3-(4-aminophenyl)-4-oxo-4H-chromen-7-yl trifluoromethanesulfonate 
• 1426688-23-4 N-(4-(7-ethynyl-4-oxo-4H-chromen-3-yl)phenyl)methanesulfonamide 
• 1426688-25-6 N-(4-(4-oxo-7-((2-oxo-1,2-dihydropyridin-4-yl)ethynyl)-4H-chromen-3-yl)phenyl)methanesulfonamide 
• 1426688-28-9 N-(4-(7-((2-tert-butoxypyridin-4-yl)ethynyl)-4-oxo-4H-chromen-3-yl)phenyl)methanesulfonamide 
• 1426688-21-2 N-(4-(4-oxo-7-((trimethylsilyl)ethynyl)-4H-chromen-3-yl)phenyl)methanesulfonamide 
• 1426687-89-9 N-(4-(7-(3-hydroxy-3-methylbut-1-ynyl)-4-oxo-4H-chromen-3-yl)phenyl)methanesulfonamide 
• 3682-01-7 daidzein diacetate 
• 486-66-8 daidzein 
• 67363-61-5 3-(2,4-Dihydroxy-phenyl)-2-(4-nitro-phenyl)-3-oxo-propionitrile 
• 67363-66-0 2-Imino-3-(4-nitro-phenyl)-2H-chromene-4,7-diol 

Relevant articles and documents

The synthesis and anti-inflammatory evaluation of 1,2,3-triazole linked isoflavone benzodiazepine hybrids

Copper catalyzed azide-alkyne cycloaddition was used for the first time to access a small series of eight novel 1,2,3-triazole linked isoflavone benzodiazepine hybrids. As part of this work, a previously unreported alkyne substituted pyrrolo[1,4]benzodiaz

Novel isoflavone derivative, preparation method therefor and medicinal use of novel isoflavone derivative

The invention relates to the field of pharmaceutical chemistry, relates to an isoflavone derivative, a preparation method therefor and medicinal use of the novel isoflavone derivative and particularlyrelates to isoflavone derivatives represented by a general formula (I) shown in the description, preparation methods therefor, pharmaceutical compositions containing these compounds and medicinal useof the isoflavone derivatives and the pharmaceutical compositions, particularly use of drugs for preventing or treating hyperlipidemia, type II diabetes, atherosclerosis and non-alcoholic fatty hepatitis.

Synthesis and biological evaluation of isoflavone amide derivatives with antihyperlipidemic and preadipocyte antiproliferative activities

A series of isoflavone amides were designed with isoflavone in place of the scaffold of 2-arylbenzoxazole as cholesterol ester transfer protein (CETP) inhibitors. Twelve new compounds were synthesized, and their inhibitory activities of CETP and preadipocyte proliferation were assayed. The hypolipidemic potency of the most effective compound HY-2c was further tested in vivo by hamster. The results indicate that HY-2c exhibited favorable antihyperlipidemic and preadipocyte antiproliferative activities.